LivaNova PLC ( (LIVN) ) has realeased its Q3 earnings. Here is a breakdown of the information LivaNova PLC presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
LivaNova PLC is a global medical technology company headquartered in London, specializing in innovative solutions for neurological and cardiac conditions. The company operates in over 100 countries, providing critical healthcare solutions across various regions.
In its third-quarter 2024 earnings report, LivaNova PLC announced a significant increase in revenue and earnings, alongside an updated full-year guidance. The company reported a third-quarter revenue of $318.1 million, reflecting an 11.2% growth compared to the prior year, and also raised its full-year guidance for 2024.
Key highlights from the report include a substantial rise in cardiopulmonary and neuromodulation revenues, which increased by 15.6% and 8.5% respectively. The company’s operating income saw a remarkable increase to $35.6 million on a GAAP basis, up from $4.5 million in the previous year. Adjusted earnings per share also rose to $0.90, indicating strong financial health and operational performance.
The company’s strategic focus on performance, innovation, and talent is evident in its financial results, with the cardiopulmonary segment driving growth due to strong sales of the Essenz Perfusion System and consumables. The neuromodulation segment saw growth primarily in the U.S. and other international markets, despite a decline in Europe.
Looking ahead, LivaNova anticipates continued revenue growth between 8.5% and 9.5% on a constant-currency basis for the full year 2024. The company’s management remains optimistic about building on its current momentum and delivering value through strategic initiatives and market expansion.
